KR20220084109A - How to prevent exposure to anticancer drugs - Google Patents

Abstract

[Problem] An object of the present invention is to provide a method for preventing exposure to an anticancer agent using a safe aqueous hypochlorous acid solution that does not affect the human body even if sprayed into space.
[Solutions] The present invention provides a method for preventing exposure to an anticancer agent, particularly, among anticancer agents, at least cyclophosphamide, 6-mercaptopurine, cisplatin, bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil, It relates to a method for preventing exposure to an anticancer agent that detoxifies any one of paclitaxel.

Description

How to prevent exposure to anticancer drugs

The present invention provides a method for preventing exposure to anticancer agents, in particular, at least one of cyclophosphamide, 6-mercaptopurine, cisplatin, bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil, and paclitaxel among anticancer agents It relates to a method of preventing exposure to anticancer drugs that detoxify.

An anticancer agent is an agent that inhibits the proliferation of cancer cells and ultimately inhibits or kills the proliferation. Its mechanism of action is to invade a target cancer cell and cause inhibition of DNA replication or synthesis in the same cell, inhibition of microtubule formation (inhibition of cell division), inhibition of intracellular metabolism or control of nutrient supply blood flow. Therefore, while an anticancer agent acts on cancerous cells and causes cell death, such as apoptosis, it has high toxicity also to normal cells. For this reason, careful handling of an anticancer agent is required.

Currently, in order to cope with various cancers, many chemotherapy using anticancer agents have been introduced. In the anticancer drug treatment, an individual patient's dose of the anticancer drug is determined by a doctor, and is dispensed into an instillation container (infusion bag) or the like by a pharmacist based on the prescription. If we look at the operation of this anticancer agent preparation in more detail, there is a primary exposure in which droplets and aerosols of anticancer agents scattered from injection needles, medicine bottles, drops, etc. adhere to the skin of a pharmacist, etc., and inhalation of these from the respiratory tract. In addition, there is a secondary exposure that is attached to the skin of a pharmacist or the like through a medicine bag or bottle in contact with the scattered anticancer drug droplets. In particular, the anticancer drug is prepared by a professional pharmacist. Therefore, the risk of occupational exposure to anticancer drugs by medical workers, such as pharmacists and nurses, is pointed out. In particular, there are reports of a miscarriage, leukemia, bladder cancer, and the like of the medical workers themselves due to long-term work engagement. Therefore, it is very important to take measures against the exposure of medical workers to anticancer drugs.

In relation to this problem, in the guidelines prepared for exposure countermeasures in cancer drug therapy (Non-Patent Document 1), it is strongly recommended to implement exposure countermeasures at the time of transport/storage and administration management of the drug solution after preparation. . In the current anticancer drug preparation work, a waterproof apron, double gloves, and an activated carbon-containing mask are worn. The anticancer drug preparation operation is carried out in an environment that reduces drug scattering, such as a biological safety cabinet that does not leak an aerosol generated during preparation, and a closed-type preparation device.

In addition, various inventions have been proposed for countermeasures against exposure to anticancer agents.

The invention related to patent document 1 absorbs urine containing a highly toxic drug such as an anticancer agent, adsorbs the drug in the urine, and is an effective anticancer agent for secondary exposure countermeasures in hospitals such as patients, medical workers, and hospital personnel Provided is a urine-absorbing sheet.

The invention related to Patent Document 2 provides an encapsulant capable of safely and easily administering an administration by reducing the possibility that a medical worker accidentally comes into contact with a chemical solution when handling an infusion bag.

The invention related to Patent Document 3 relates to a more effective leak prevention measure and leak prevention measure from a drug combination device and a drug administration device for a drug that has a risk of causing adverse health effects if leaked, and concurrent administration of a plurality of drugs It provides a new means of safety, low-cost, and simple implementation of leak prevention measures, leak prevention measures, and identification of solution leak sites in the

The invention related to Patent Document 4 provides an anticancer drug adsorption sheet that exhibits a sufficient effect for adsorption and retention of highly toxic drugs such as anticancer drugs and further improves the safety of health care workers in a medical environment.

The invention according to Patent Document 5 provides an infusion tube set and a method for using the same, effectively reducing the risk of exposure to dangerous drugs such as anticancer drugs.

However, in the inventions of Patent Documents 1 to 5, the effect of reducing exposure is limited to the prevention of leakage from the appliance, and in fact, environmental contamination cannot be completely prevented.

In addition, in the above guideline P66, with respect to the handling of excreta and body fluids of patients 48 hours after administration of the anticancer drug, "caution is urged to minimize scattering to the surroundings during excretion. For example, if possible, both male and female aquaculture Men use the toilet and urinate in a sitting position. Close the lid of the flush toilet before flushing.", P68, as the cleaning procedure when anticancer drugs overflow, "clean the area overflowing with anticancer drugs with detergent." Wash with (for cleaning) and repeat “rinsing with water” multiple times. Or, if there is a drug that inactivates anticancer drugs, wipe it off, let it soak into paper or cloth, wash it, and finally wipe with a dry cloth.” described, and examples of the drug include sodium hypochlorite solution and sodium hydroxide, and in particular, it has been confirmed that 5.25% sodium hypochlorite is effective as some anticancer drugs.

Patent Document 1: Japanese Patent Laid-Open No. 2018-126316 Patent Document 2: Japanese Patent Laid-Open No. 2018-122023 Patent Document 3: Japanese Patent Publication No. 6117973 Patent Document 4: Japanese Patent Publication No. 6092445 Patent Document 5: Japanese Patent Laid-Open No. 2014-217555

Non-Patent Document 1: Japanese Cancer Nursing Association, Japanese Society for Clinical Oncology, Japanese Society for Clinical Oncology, Japanese Society of Clinical Oncology Co-edited, "Joint Guidelines for Exposure Countermeasures in Cancer Drug Therapy, 2015 Edition", Kanehara Publishing Co., Ltd., issued on October 15, 2015, P. 66-68

However, it has been confirmed and proven that a trace amount of an anticancer agent contained in urine or excrement is splashed into the space or floor in the toilet used by patients receiving anticancer drug administration, and health by indirectly inhaling the anticancer drug by a normal person damage is feared.

In addition, as described above, sodium hypochlorite, which is believed to be effective in neutralizing anticancer drugs, is a so-called liquid chlorine-based bleach that is commercially available, but contains an alkali agent and is dangerous because chlorine gas is generated when mixed with an acidic detergent, The label says "Do not mix, dangerous" etc. The alkali agent exists to prevent the decomposition of sodium hypochlorite in the container, but since it is strongly alkaline, it is necessary to wear rubber gloves. Moreover, toxicity by volatilization is also pointed out as for the liquid chlorine-type bleaching agent marketed, and it cannot spray into space. For this reason, it has become clear that, in medical and nursing care settings, in particular, in toilets used by patients receiving drug administration, trace amounts of drugs contained in urine or excrement are splashed into spaces or floors, Health damage by this indirect suction is concerned.

Then, in view of the said problem, this invention is providing the method of detoxifying an anticancer agent, especially an alkylating agent, using the safe aqueous hypochlorous acid solution which does not affect the human body even if it sprays into space. That is, the present invention is used for the use of anticancer drug exposure prevention by spraying the hypochlorous acid aqueous solution developed by the applicant.

In order to achieve the above object, the present invention provides at least cyclophosphamide, 6-mercaptopurine, cisplatin, benda among anticancer agents by spraying an aqueous solution of hypochlorous acid to a target to be treated or toward a space in which the target to be treated is present. It is characterized in that it is an anticancer drug exposure prevention method that detoxifies any one of mustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil, and paclitaxel. In addition, the hypochlorous acid aqueous solution is accommodated and the hypochlorous acid aqueous solution is sprayed with a gaseous or misty atomizer. In addition, you may perform spraying with the ultrasonic spraying apparatus which accommodates the hypochlorous acid aqueous solution. In addition, the pH of the aqueous hypochlorous acid solution is suitable in it being 5.5-7.0.

In addition, the present invention is characterized in that paclitaxel is detoxified by spraying an aqueous hypochlorous acid solution toward the target to be treated and leaving it for 24 hours.

According to the method of using the anticancer agent neutralizing agent according to the present invention, by spraying the hypochlorous acid aqueous solution, it is possible to safely and efficiently prevent the anticancer agent exposure.

1 : is a figure which shows a mode that hypochlorous acid aqueous solution is sprayed toward a toilet bowl.
Fig. 2 is a view showing a state in which an aqueous solution of hypochlorous acid is sprayed toward a space where a target to be treated exists.

Hereinafter, an embodiment of the present invention will be described in detail with reference to the drawings. In each figure, the same number is attached|subjected to the same part, and overlapping description is abbreviate|omitted. In addition, please note that drawings may be exaggeratedly expressed in order to understand this invention, and are not necessarily shown precisely. In addition, the technical scope of this invention is not limited to the specific use, shape, dimension, etc. which were shown in the following embodiment. EMBODIMENT OF THE INVENTION Hereinafter, embodiment of this invention is described, referring drawings.

The inventor of this application invented the manufacturing method and manufacturing apparatus of the slightly acidic aqueous hypochlorous acid solution which can maintain the pH value at the constant value in the range of 5.5-7.0 over a long period (patent 6553955). For details, please refer to the said patent publication. It should be understood that the present invention proposes a method of using a neutralizing agent that safely and efficiently prevents exposure to an anticancer agent by using an aqueous solution of hypochlorous acid prepared by the above-mentioned production method and spraying it into a space.

Example 1

The present invention provides at least cyclophosphamide, 6-mercaptopurine, cisplatin, bendamustine, gemcitabine, and oxaliplatin among anticancer agents by spraying an aqueous solution of hypochlorous acid to a target to be treated or to a space in which the target to be treated is present. , vincristine, doxorubicin, fluorouracil, characterized in that it is a method of preventing exposure to anticancer drugs to detoxify any one of paclitaxel. In addition, the hypochlorous acid aqueous solution is accommodated and the hypochlorous acid aqueous solution is sprayed with a gaseous or misty atomizer. In addition, the pH of the aqueous hypochlorous acid solution is suitable in it being 5.5-7.0.

The alkylating agent is any one of ifosfamide, cyclophosphamide, dacarbazine, temozolomide, nimustine, busulfan, procarbazine, melparan, and ranimustine. The alkylating agent is a representative drug of a cytotoxic anticancer agent. The alkylating agent attaches a mass of atoms called an alkyl group to the DNA of cancer cells, and binds two DNA twisted in a spiral into an abnormal shape, making DNA replication impossible. If the cancer cells continue to divide and multiply while the alkylation group is attached, the DNA is cut and the cancer cells die. Among them, cyclophosphamide (endoxane) is one of the most commonly used anticancer drugs, and is used as a central drug for CAV therapy for small cell lung cancer and CHOP therapy for malignant lymphoma, and is sometimes used alone. .

The method for producing an aqueous hypochlorous acid solution of the present invention comprises: a) a first step of supplying raw water to a storage tank; b) supplying an acidic aqueous solution while stirring the raw water in the storage tank, mixing raw water and acidic aqueous solution A second step of producing an aqueous solution, c) after the second step, a third step of supplying sodium hypochlorite while stirring the mixed aqueous solution in the storage tank to produce an aqueous hypochlorous acid solution, d) after the third step, The supply of the acidic aqueous solution and the supply of the sodium hypochlorite are repeated in this order until the pH value of the aqueous hypochlorite solution is stably maintained at a constant value in the range of 5.5 to 7.0 for 1 minute or longer A 4th process is provided.

The pH value of the aqueous hypochlorous acid solution produced in the above-mentioned process is controlled to a constant value in the range of 5.5 to 7.0, preferably to a constant value in the range of 6.0 to 7.0, more preferably to 7.0. That is, since the pH value of the hypochlorous acid aqueous solution is about the same as the pH value of human skin, there is very little influence on the human body, and it can be evaluated that it is excellent in safety.

See FIG. 1 . 1 : is a figure which shows a mode that the hypochlorous acid aqueous solution (1) is sprayed toward a toilet bowl. As shown in FIG. 1, the atomizer 10 accommodates the hypochlorous acid aqueous solution 1, and it sprays and uses it by handle operation toward a toilet bowl. The atomizer 10 may use a generally commercially available atomizer. Moreover, it is also possible to use the hypochlorous acid aqueous solution 1 by spraying toward the space where the to-be-processed object exists, or after processing a to-be-processed object, or a space.

Example 2

Example 2 will be described in detail. Since the applicant of this application implemented the anticancer drug decomposition performance confirmation test with respect to the hypochlorous acid aqueous solution which concerns on this application, this is demonstrated.

The test was conducted from September 25 to 27, 2019, with Shionogi Pharma Co., Ltd. (Class 5, Mishima 2-chome 2-chome, Osaka Prefecture) as the test site. As the test method, LC/MS/MS was employed.

First, with respect to the preparation of the test substance solution, add 5 mL of physiological saline to 100 mg of cyclophosphamide to make a stock solution (20 mL), accurately weigh 1 mL of the stock solution, add purified water, and accurately 20 mL do it with Again, 5 mL of this solution was accurately weighed, purified water was added to make exactly 50 mL, and it was used as a test substance solution (100 µg/mL).

As the decomposition liquid A, 1 mL of the above-mentioned test substance solution is added to 9 mL of the hypochlorous acid aqueous solution used in this application and shaken, and let it be the sample solution (decomposition liquid A). This solution is measured immediately after preparation, and this operation is repeated 3 times.

As the decomposition solution B, 1 mL of the above-mentioned test substance solution is added to 9 mL of 10-fold diluted strong alkaline electrolyzed water (P.W-No. 135) and shaken to obtain a sample solution (decomposition solution B). This solution is measured immediately after preparation, and this operation is repeated 3 times. In addition, strong alkaline electrolyzed water (P.W-No. 135) assumes general cleaning, and is using the solution diluted 10-fold.

In addition, as a control solution, 1 mL of the above-mentioned test substance solution was added to 9 mL of purified water and shaken to obtain a sample solution. This solution is measured immediately after preparation, and this operation is repeated 3 times.

Each decomposition solution prepared in the above manner was measured using LC/MS/MS. Then, the decomposition liquid A and the decomposition liquid B were compared with the control solution, and the respective decomposition effects were confirmed.

As a result of the confirmation test, as shown in Table 1, with respect to cyclophosphamide, the average decomposition rate of the decomposition solution A was 99.5%, while the average decomposition rate of the decomposition solution B was 4.0%.

Test Investigation Content: Anti-cancer drug degradation performance confirmation test

Exam registration number: JF19-G047

Test location: Shionogi Pharma Co., Ltd. (Class 5, 1 High School, Mishima 2-chome, Setsushi City, Osaka Prefecture)

Test Date: September 25-27, 2019

Assay: LC/MS/MS

Sample: cyclophosphamide (endoxane for injection 100 mg)

Decomposition solution A: aqueous solution of hypochlorous acid used herein

Decomposition liquid B: Strong alkali electrolyzed water (P.W-No. 135)

As a result, it was proved that the aqueous hypochlorous acid solution used in Example 1 decomposed 99% or more of cyclophosphamide on average.

Example 3

Example 3 will be described in detail.

See FIG. 2 . As shown in FIG. 2, the ultrasonic atomizing apparatus 20 is equipped with the floor of a space. The ultrasonic spraying device accommodates the hypochlorous acid aqueous solution 1 in the tank, and neutralizes a trace amount of the anticancer agent remaining in the space by discharging the hypochlorous acid aqueous solution 1 in the form of mist into the space. In addition, with the power of ultrasonic waves, the particle diameter related to misting of the spray can be made into ultra-fine particles of about 4 to 5 micrometers, so that it can be sprayed smoothly and efficiently to every corner of the space. In addition, since the hypochlorous acid aqueous solution (1) is made of safe ingredients, there is no effect on health even if the atomized mist is inhaled.

As a method of use, at the time of a start, continuous operation for about 10 to 20 minutes is performed, and the hypochlorous acid aqueous solution 1 is roughly spread in space. Once, the hypochlorous acid aqueous solution (1) spreads widely in the space, thereafter, the effect of neutralizing the drug by additional spraying continues.

In addition, in Example 3, with implementation of the spraying by the ultrasonic spraying apparatus 20 which accommodates the hypochlorous acid aqueous solution 1, since the applicant of this application implemented the solution concentration measurement test, this is demonstrated. The test was conducted from July 19 to 26, 2019 with Shionogi Pharma Co., Ltd. (Class 5, Mishima 2-chome 2-chome, Osaka Prefecture) as the test site. For the test method, LC/MS/MS was employed, and the measured value (ng/mL) and the detected amount (µg) were confirmed with respect to the target drug for cyclophosphamide. 100 µg of cyclophosphamide was applied to each of 10 10 cm x 10 cm sampling sheets, dried completely, and then 20 mL of an aqueous hypochlorous acid solution according to the present application was further added, and left for 1 minute. Then, using two gauze sheets, it was sufficiently wiped off, and the cyclophosphamide remaining on the sheet was measured.

As shown in Table 2, for all samples, the detection limit was 0.02/mL. In addition, the measured value became 1.20-15.7 ng/mL.

Test Investigation Content: Anti-cancer drug concentration test

Exam registration number: JF19-G019

Test location: Shionogi Pharma Co., Ltd. (Class 5, 1 High School, Mishima 2-chome, Setsushi City, Osaka Prefecture)

Test Date: July 19-26, 2019

Assay: LC/MS/MS

Target drug: 100 μg of cyclophosphamide added

Example 4

Example 4 will be described in detail. Since the applicant of this application performed another anticancer drug decomposition performance confirmation test with respect to the aqueous hypochlorous acid solution which concerns on this application, this is demonstrated.

The test was conducted from January 9 to February 12, 2020 with Shionogi Pharma Co., Ltd. (Class 5, Mishima 2-chome 2-chome, Osaka Prefecture) as the test site. As the test method, LC/MS/MS was employed.

First, for the preparation of the test substance solution, add 5 mL of physiological saline to 100 mg each of 6-mercaptopurine and cisplatin to make a stock solution (20 mL), measure 1 mL of the stock solution accurately, and add purified water and make exactly 20 mL. Again, 5 mL of this solution was accurately weighed, purified water was added to make exactly 50 mL, and it was used as a test substance solution (100 µg/mL).

As the decomposition solution A, 1 mL of the above-mentioned test substance solution is added to 9 mL of the hypochlorous acid aqueous solution used in this application, and shaken is used as a sample solution (decomposition solution A). This solution is measured immediately after preparation, and this operation is repeated 3 times.

As a control solution, 1 mL of the above test substance solution is added to 9 mL of purified water and shaken to obtain a sample solution. This solution is measured immediately after preparation, and this operation is repeated 3 times.

The decomposition solution A and purified water prepared in the above manner were measured using LC/MS/MS, and the decomposition effect of each test substance was confirmed by comparing the decomposition solution A with purified water as a control solution. Table 3 below shows the test results for 6-mercaptopurine and Table 4 for cisplatin.

As a result of the confirmation test, as shown in Tables 3 and 4, the average decomposition rates of the decomposition solution A were 95% and 99.2% for 6-mercaptopurine and cisplatin, respectively.

Test investigation content: Anticancer drug degradation performance confirmation test

Exam number: JF19-M010, M012

Test location: Shionogi Pharma Co., Ltd. (Class 5, 1 High School, Mishima 2-chome, Setsushi City, Osaka Prefecture)

Exam date: January 9th - February 12th, 2020

Assay: LC/MS/MS

Sample: 6-mercaptopurine, cisplatin

Decomposition solution A: aqueous solution of hypochlorous acid used herein

As a result, it was proved that the aqueous hypochlorous acid solution used in Example 1 decomposes on average 95% and 99.2% of 6-mercaptopurine and cisplatin, respectively.

Example 5

Example 5 will be described in detail. Since the applicant of this application performed another anticancer drug decomposition performance confirmation test with respect to the hypochlorous acid aqueous solution which concerns on this application, this is demonstrated.

The test was conducted from August 31 to October 27, 2020, with Shionogi Pharma Co., Ltd. (Class 5, Mishima 2-chome 2-chome, Osaka Prefecture) as the test site. As the test method, LC/MS/MS was employed.

First, with respect to the preparation of the test substance solution, each 100 mg of bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, and fluorouracil was dissolved by adding 5 mL of physiological saline to make a stock solution (20 mL), and the stock solution Accurately weigh 1 mL, add purified water to make exactly 20 mL. Again, 5 mL of this solution was accurately weighed, purified water was added, and the volume was made exactly 50 mL to obtain a test substance solution (100 µg/mL).

As the decomposition solution A, 1 mL of the above-mentioned test substance solution is added to 9 mL of the hypochlorous acid aqueous solution used in this application, and shaken is used as a sample solution (decomposition solution A). This solution is measured immediately after preparation, and this operation is repeated 3 times.

As a control solution, 1 mL of the above test substance solution is added to 9 mL of purified water and shaken to obtain a sample solution. This solution is measured immediately after preparation, and this operation is repeated 3 times.

The decomposition solution A and purified water prepared in the above manner were measured using LC/MS/MS, and the decomposition effect of each test substance was confirmed by comparing the decomposition solution A with purified water as a control solution.

As a result of the confirmation test, Table 5 shows bendamustine, gemcitabine, and oxaliplatin, and Table 6 shows vincristine, doxorubicin, and fluorouracil, and the average degradation rates of the degradation solution A are 100% and 99.5%, respectively. , 99.8%, 100%, 99.9%, 100%.

Test investigation content: Anticancer drug degradation performance confirmation test

Exam registration number: JF20-G003, H002, H003, K011, K012, J008

Test location: Shionogi Pharma Co., Ltd. (Class 5, 1 High School, Mishima 2-chome, Setsushi City, Osaka Prefecture)

Test Date: August 27 - August 31, 2020 (Bendamustine)

September 9 - September 14, 2020 (Gemcitabine)

August 28 - September 1, 2020 (oxaliplatin)

October 22 - October 27, 2020 (Vin Christine)

October 23 - October 27, 2020 (doxorubicin)

September 28 - October 5, 2020 (Fluorouracil)

Assay: LC/MS/MS

Sample: bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil

Decomposition solution A: aqueous solution of hypochlorous acid used herein

As a result, the aqueous hypochlorous acid solution used in Example 1 was 100%, 99.5%, 99.8%, 100%, 99.9%, 100% with respect to bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, and fluorouracil, respectively. It has been proven to resolve %.

Example 6

Example 6 will be described in detail. Since the applicant of this application implemented the anticancer drug degradation performance confirmation test with respect to paclitaxel with respect to the hypochlorous acid aqueous solution which concerns on this application, this is demonstrated.

The test was conducted twice, on February 12 and October 2-13, 2020, with Shionogi Pharma Co., Ltd. (Class 5, Mishima 2-chome, Setsushi City, Osaka Prefecture) as the test site. As the test method, LC/MS/MS was employed.

First, for the preparation of the test substance solution, add 5 mL of physiological saline to 100 mg of paclitaxel to make a stock solution (20 mL), accurately weigh 1 mL of the stock solution, add purified water, and make exactly 20 mL. Again, 5 mL of this solution was accurately weighed, purified water was added, and the volume was made exactly 50 mL to obtain a test substance solution (100 µg/mL).

As the decomposition solution A, 1 mL of the above-mentioned test substance solution is added to 9 mL of the hypochlorous acid aqueous solution used in this application, and shaken is used as a sample solution (decomposition solution A). This solution is measured immediately after preparation, and this operation is repeated 3 times. As a control solution, 1 mL of the above test substance solution is added to 9 mL of purified water and shaken to obtain a sample solution. This solution is measured immediately after preparation, and this operation is repeated 3 times.

Each decomposition solution prepared in the above manner was measured using LC/MS/MS. Then, the decomposition solution A and the control solution were compared to confirm the decomposition effect of the decomposition solution A. Table 7 below shows the measurement results immediately, and Table 8 shows the test results after 24 hours.

As a result of the confirmation test conducted on February 12, 2020, as shown in Table 6, with respect to paclitaxel, the average decomposition rate of the decomposition solution A was 1.3%. That is, the decomposition effect of the decomposition liquid A was not confirmed with respect to paclitaxel.

However, in the test on October 2 to 13, 2020, after increasing the concentration 10 times that of the decomposition solution A carried out on February 12, 2020, the detection amount of paclitaxel was measured 24 hours later, as a result of decomposition The average decomposition rate of the liquid A was 99.1%.

Test investigation content: Anticancer drug degradation performance confirmation test

Exam registration number: JF20-K004

Test location: Shionogi Pharma Co., Ltd. (Class 5, 1 High School, Mishima 2-chome, Setsushi City, Osaka Prefecture)

Exam dates: February 12 and October 2-13, 2020

Assay: LC/MS/MS

Sample: Paclitaxel

Decomposition solution A: aqueous solution of hypochlorous acid used herein

As a result, it was proved that the aqueous hypochlorous acid solution used in Example 6 was difficult to decompose immediately with respect to paclitaxel, but when the concentration was increased and a certain period of time elapsed, it was demonstrated that 99.1% of the aqueous solution was decomposed.

As mentioned above, although the Example of the usage method of the anticancer agent neutralizing agent which concerns on this invention was demonstrated, it will be understood that various changes are possible without deviating from the technical scope of this invention.

(Industrial Applicability)

According to the anticancer agent exposure prevention method according to the present invention, by spraying an aqueous solution of hypochlorous acid, it is possible to safely and efficiently prevent anticancer agent exposure, so that not only medical facilities such as hospitals, but also residential spaces or toilets of elderly facilities or residences, In addition, it can be widely applied to the prevention of exposure to anticancer drugs in animal hospitals and the like.

1: Hypochlorous acid aqueous solution
10: atomizer
20: ultrasonic nebulizer

Claims (6)

By spraying an aqueous hypochlorous acid solution toward the target to be treated, at least any of cyclophosphamide, 6-mercaptopurine, cisplatin, bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil, and paclitaxel among anticancer drugs How to prevent exposure to anticancer drugs to detoxify one. By spraying an aqueous solution of hypochlorous acid into the space where the target to be treated exists, at least cyclophosphamide, 6-mercaptopurine, cisplatin, bendamustine, gemcitabine, oxaliplatin, vincristine, doxorubicin, fluorouracil among anticancer drugs. , a method for preventing exposure to an anticancer agent that detoxifies any one of paclitaxel. 3. The method of claim 1 or 2,
Anticancer agent exposure prevention method, characterized in that the hypochlorous acid aqueous solution is accommodated and the hypochlorous acid aqueous solution is sprayed with a gas or mist. 3. The method of claim 2,
Anticancer agent exposure prevention method, characterized in that it is sprayed by an ultrasonic spray device containing the hypochlorous acid aqueous solution. 5. The method according to any one of claims 1 to 4,
The pH of the hypochlorous acid aqueous solution is 5.5-7.0 anticancer agent exposure prevention method. An anticancer drug exposure prevention method, characterized in that the hypochlorous acid aqueous solution is sprayed toward the target to be treated and left for 24 hours to detoxify paclitaxel.

Images